Liaoning Chengda Biotechnology Co. Ltd. Class A

As of June 30, 2026, Liaoning Chengda Biotechnology Co. Ltd. Class A carries a market capitalization of 8.12B, placing it among publicly traded companies globally. Its enterprise value stands at 3.00B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Liaoning Chengda Biotechnology Co. Ltd. Class A's next confirmed earnings release is scheduled for October 30, 2026.

As of June 30, 2026, Liaoning Chengda Biotechnology Co. Ltd. Class A has 416.45M shares outstanding.

These figures are as of June 30, 2026.

As of June 30, 2026, Liaoning Chengda Biotechnology Co. Ltd. Class A maintains a current ratio of 24.57, meaning it holds 24.6x the short-term assets needed to cover near-term liabilities.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Liaoning Chengda Biotechnology Co. Ltd. Class A recorded 13.15M in income tax expense.

As of the close on October 22, 2026, Liaoning Chengda Biotechnology Co. Ltd. Class A's stock has declined approximately 27.14% over the past 52 weeks. The 50-day moving average sits at 20.57, while the 200-day moving average is 22.71.

As of June 30, 2026, Liaoning Chengda Biotechnology Co. Ltd. Class A holds 5.12B in cash and equivalents against 7.12M in total debt, resulting in a net debt position of -3.59B. Total book value stands at 9.34B, with working capital of 6.51B providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Liaoning Chengda Biotechnology Co. Ltd. Class A paid dividends of 0.10 per share.